Sandoz Group AG (SW:SDZ) — Market Cap & Net Worth
Market Cap & Net Worth: Sandoz Group AG (SDZ)
Sandoz Group AG (SW:SDZ) has a market capitalization of $35.57 Billion (CHF28.13 Billion) as of April 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #789 globally and #8 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sandoz Group AG's stock price CHF65.32 by its total outstanding shares 430701660 (430.70 Million).
Sandoz Group AG Market Cap History: 2023 to 2026
Sandoz Group AG's market capitalization history from 2023 to 2026. Data shows growth from $14.52 Billion to $35.57 Billion (37.59% CAGR).
Sandoz Group AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sandoz Group AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.22x
Sandoz Group AG's market cap is 2.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
20239.93x
Sandoz Group AG's market cap is 20239.93 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2023 | $14.52 Billion | $9.98 Billion | $77.00 Million | 1.46x | 188.58x |
| 2024 | $20.24 Billion | $9.12 Billion | $1.00 Million | 2.22x | 20239.93x |
Competitor Companies of SDZ by Market Capitalization
Companies near Sandoz Group AG in the global market cap rankings as of April 18, 2026.
Key companies related to Sandoz Group AG by market ranking:
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #427 globally with a market cap of $53.65 Billion USD ( CN¥366.60 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #442 globally with a market cap of $52.46 Billion USD.
- HANSOH PHARMAC. HD-00001 (F:3KY): Ranked #972 globally with a market cap of $23.69 Billion USD ( €20.26 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #518 globally with a market cap of $45.32 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #427 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $53.65 Billion | CN¥57.47 |
| #442 | Zoetis Inc | NYSE:ZTS | $52.46 Billion | $119.04 |
| #972 | HANSOH PHARMAC. HD-00001 | F:3KY | $23.69 Billion | €4.29 |
| #518 | GALDERMA GROUP AG | NYSE:GALDY | $45.32 Billion | $38.65 |
Sandoz Group AG Historical Marketcap From 2023 to 2026
Between 2023 and today, Sandoz Group AG's market cap moved from $14.52 Billion to $ 35.57 Billion, with a yearly change of 37.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF35.57 Billion | +12.93% |
| 2025 | CHF31.50 Billion | +55.61% |
| 2024 | CHF20.24 Billion | +39.38% |
| 2023 | CHF14.52 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 17th, 2026 the market cap of Sandoz Group AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $35.57 Billion USD |
| MoneyControl | $35.57 Billion USD |
| MarketWatch | $35.57 Billion USD |
| marketcap.company | $35.57 Billion USD |
| Reuters | $35.57 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage f… Read more